Table 6 Antimicrobial susceptibility profiles of microorganisms implicated in MC-CRBSI episodes
From: Surveillance of catheter-related infections: the supplementary role of the microbiology laboratory
Antimicrobial susceptibility profile according to antimicrobial category | % isolates resistant | |||||
|---|---|---|---|---|---|---|
S. epidermidis (n = 55) | S. aureus (n = 16) | A. baumannii complex (n = 35) | E. cloacae (n = 17) | P. aeruginosa (n = 14) | K. pneumoniae (n = 12) | |
Anti-staphylococcal β-lactams (oxacillin) | 96 | 75 | - | - | - | - |
Penicillin (ampicillin) | - | - | - | - | - | 100 |
β-lactamase inhibitors (amoxicillin/clavulanic acid) | - | - | 100 | - | - | 33 |
β-lactamase inhibitors (piperacillin/tazobactam) | - | - | - | 53 | 36 | 33 |
Cephamycins (cefoxitin) | - | - | - | - | - | 17 |
Non-ES cephalosporins (cefuroxime) | - | - | - | 71 | - | 33 |
ES cephalosporins (cefotaxime#, ceftazidime, cefepime) | - | - | 100 | 53 | 21 | 33 |
Carbapenems (ertapenem#, meropenem, imipenem) | - | - | 100 | 18 | 36 | 0 |
Aminoglycosides (amikacin*, gentamicin) | 80 | 63 | 86 | 0 | 14 | 17 |
Fluoroquinolones (ciprofloxacin, moxifloxacin^) | 55 | 75 | 49 | 0 | 14 | 17 |
Macrolides (erythromycin) | 84 | 75 | - | - | - | - |
Linosamides (clindamycin) | 76 | 63 | - | - | - | - |
Linezolid | 0 | 0 | - | - | - | - |
Glycopeptides (teicoplanin, vancomycin) | 0 | 0 | - | - | - | - |
Tetracycline | 93 | 63 | - | - | - | - |
Glycylcycline (tigecycline) | 0 | 0 | 3 | 12 | - | 17 |
Fusidic acid | 24 | 0 | - | - | - | - |
Rifampicin | 47 | 19 | - | - | - | - |
Polymyxins (colistin) | - | - | 0 | 6 | 14 | 0 |
Folate pathway inhibitors (trimethoprim/ sulphamethoxazole) | 78 | 75 | - | 12 | - | 17 |
Acquired resistance profiles | ||||||
S | 11 | 25 | 0 | 47 | 79 | 67 |
MDR | 89 | 75 | 0 | 53 | 7 | 33 |
XDR | 0 | 0 | 100 | 0 | 0 | 0 |
PDR | 0 | 0 | 0 | 0 | 14 | 0 |